SavedAdd your journal

Journals / Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri Ve Biyoteknoloji / 2019 / Cilt: 8 Sayı: 2

BISBENZOXAZOLE DERIVATIVES HAD ANTI-PROLIFERATIVE EFFECT ON HUMAN CANCER CELLS

Furkan AYAZ
Qadar Ahmed ISSE
Rusmeenee KHEEREE
Ronak Haj ERSAN
Oztekin ALGUL
Pages
203–211
Publication Date
2019-07-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results suggest that they can be highly potent since they were biologically active even at low concentration ranges.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT A series of symmetric bis-benzoxazole derivatives were synthesized using one-pot cyclisation reaction between 4-fluoro substituted 2-aminophenol and suitable carboxylic acids.
📊
Key Findings & Data:Synthesized compounds’ anticancer activities were tested by using MTT assay on human prostate (DU145) and breast (MCF7) cancer cells.
💡
Conclusion & Impact:Our results suggest that they can be highly potent since they were biologically active even at low concentration ranges.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Bisbenzoxazole · Breast cancer · Prostate cancer

Abstract

ABSTRACT A series of symmetric bis-benzoxazole derivatives were synthesized using one-pot cyclisation reaction between 4-fluoro substituted 2-aminophenol and suitable carboxylic acids. Synthesized compounds’ anticancer activities were tested by using MTT assay on human prostate (DU145) and breast (MCF7) cancer cells. Screening results revealed that all compounds possessed a high level anti-cancer potential by significantly decreasing the cell proliferation in prostate and breast cancer cell lines. Our compounds exerted their anti-proliferative effects in a dose and time dependent manner. Our results suggest that they can be highly potent since they were biologically active even at low concentration ranges. Our study presents a series of new bis-benzoxazole based compounds with potential therapeutic effects against tumor cells. Therefore, characterization of new generation bis-benzoxazole derivatives will have a significant contribution on the development of new era anti-cancer drug candidates.

Özet

ABSTRACT A series of symmetric bis-benzoxazole derivatives were synthesized using one-pot cyclisation reaction between 4-fluoro substituted 2-aminophenol and suitable carboxylic acids. Synthesized compounds’ anticancer activities were tested by using MTT assay on human prostate (DU145) and breast (MCF7) cancer cells. Screening results revealed that all compounds possessed a high level anti-cancer potential by significantly decreasing the cell proliferation in prostate and breast cancer cell lines. Our compounds exerted their anti-proliferative effects in a dose and time dependent manner. Our results suggest that they can be highly potent since they were biologically active even at low concentration ranges. Our study presents a series of new bis-benzoxazole based compounds with potential therapeutic effects against tumor cells. Therefore, characterization of new generation bis-benzoxazole derivatives will have a significant contribution on the development of new era anti-cancer drug candidates.

🔖

Cite This Article

AYAZ, F., ISSE, Q. A., KHEEREE, R., ERSAN, R. H., ALGUL, O. (2019). BISBENZOXAZOLE DERIVATIVES HAD ANTI-PROLIFERATIVE EFFECT ON HUMAN CANCER CELLS. Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri Ve Biyoteknoloji, Cilt: 8 Sayı: 2, 203–211. https://ajindex.com/articles/905317

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Williams GH, Stoeber K. Cell cycle markers in clinical oncology. CurrOpin Cell Biol 2007; 19: 1- 6
  2. Bower JJ et al. Topoisomerase IIalpha maintains genomic stability through decatenationG(2) checkpoint signaling. Oncogene 2010; 29: 4787–4799
  3. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science1994; 266: 1821–1828
  4. Marie Classon EH. The retinoblastoma tumor suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910–917
  5. Xu B, Kim ST, Kastan MB. Involvement of Brca1 in S-Phase and G2-Phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445–3450
  6. Rui-Hong Wang HY, Chu-Xia Deng. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci 2004; 101: 17108–17113
  7. Santarpia L, et al. DNA repair gene patters as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013; 18: 1063–1073
  8. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001; 98: 10869–10874
  9. Nakagawa T, et al. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines. Cancer Res 2004; 64: 4826–4832
  10. Hinck L, Näthke I. Changes in cell and tissue organization in cancer of the breast and colon. Curr Opin Cell Biol 2014;0:87–95
  11. Cho EH, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 2012; 9: 016001
  12. De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do?. Virchows Archiv 2016; 468: (397)
  13. Gustavsson B, et al. A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clin Col Canc 2015; 14: 1
  14. Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer. BioMedicine 2017; 7(4): 23
  15. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of internal medicine. 18th ed. New York: McGraw-Hill Companies, 2011
  16. Andreae S. Lexikon der Krankheiten und Untersuchungen. Stuttgart: Thieme, 2008
  17. Hu Q, Sun W, Wang C, Gu Z. Recent Advances of Cocktail Chemotherapy by Combination Drug Delivery Systems. Adv. Drug Deliv. Rev. 2016; 98: 19–34
  18. Hoelder S, Clarke PA, Workman P. Discover